

Placement of Entitlement Offer Shortfall

Highlights

- **Placement of Entitlement Offer Shortfall to raise ~A\$2.7m, supported by a range of new and existing sophisticated investors**
- **Aggregate amount to be raised under the Entitlement Offer totals ~A\$8.5M**
- **New funding further strengthens balance sheet and provides further flexibility to support ongoing clinical development and commercialisation initiatives associated with NUZ-001, and for working capital (potential to reduce drawdown of the convertible note facility)**

16 April 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that it has received firm commitments to raise A\$2,657,000 to partially place the shortfall arising from its recently completed pro rata non-renounceable entitlement offer (**Entitlement Offer**) announced on 23 December 2025, which sought to raise up to approximately A\$17.1 million.

The Entitlement Offer closed at 5.00pm (AEDT) on 21 January 2026 raising approximately A\$5.9 million, resulting in a shortfall of ~A\$11.3 million (**Entitlement Offer Shortfall**) (refer ASX announcement: 27 January 2026). 33,212,500 new fully paid ordinary shares in the Company ("New Shares") will be issued under the Entitlement Offer Shortfall at the same subscription price as that under the Entitlement Offer (being \$0.08 per New Share). New Shares to be issued under the Entitlement Offer Shortfall are expected to be listed on ASX and rank pari-passu with the existing fully paid ordinary shares of Neurizon from their date of issue. Settlement of these New Shares is expected to occur on 20 April 2026, with allotment on 21 April 2026.

New funding provides additional financial flexibility to advance clinical development and commercialisation initiatives associated with lead asset, NUZ-001, and for working capital (potential to reduce drawdown of the convertible note facility). The Company remains focused on disciplined execution across its clinical, regulatory and corporate priorities, as it advances NUZ-001 through Phase 2/3 clinical development and towards near-term milestones.

Interim Executive Chair, Mr Sergio Duchini said: "We are pleased to have concluded the Entitlement Offer Shortfall placement with the support of a number of new and existing sophisticated investors.

Importantly, the Company remains funded for participation in the HEALEY ALS Platform Trial. With this in mind, we have taken a disciplined approach to the shortfall that aligns with our strategic priorities.

This additional capital further strengthens the balance sheet and provides increased flexibility as we progress towards key clinical milestones and position NUZ-001 for potential commercialisation."

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics

Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations

Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations

Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited